Synairgen Share Discussion Threads

[pdt] 13/4/2020 13:44

Excellent find. Thanks for posting Likya

Now with some evidence of efficacy using inhaled IFN alpha in Covid patients we should be encouraged for results in IFN beta 1a being used by SNG, which research suggests should be the better subtype candidate for therapy. Also SNG are ahead being in a placebo controlled trial with prior safety data.

Great having this board to feed us all the bits of the puzzle. Well done Nobby.

[ferris_bueller] 13/4/2020 13:41

Have been invested here for sometime now, but still continue to dig out as much info as possible to underpin the belief I have in this company, SNG001, and my investment.

It is a without a shadow of a doubt that this board has 2 of the best and knowledgeable posters one could ever ask for in (Nobby & timbo). I had the pleasure of their expertise a couple of years back on the TYRU Tyratech investment.

Synairgen

The more I read (historical & current) the more I am convinced that SNG001 is a winner.

From the historical COPD SG016 phase I & II trials (before phase II was paused due to covid 19 ) it is already evident that this is something special.

In 2012 Leanne Metcalf, Assistant Director of Research at Asthma UK :

"This has the potential to be one of the biggest breakthroughs in asthma treatments in the past 20 years. This clinical trial demonstrates the potential of this anti-viral drug to prevent asthma attacks for thousands of people with severe asthma."

Also interesting from 2012 :

Findings from Southampton's original body of research are also shaping the development of novel treatments for other serious viral infections such as avian and swine flu, driving collaborations with the Public Health England (formerly Health Protection Agency) and the US Department of Defense.

Furthermore :

During the Phase I and Phase II clinical trials Synairgen linked with researchers in NIHR Biomedical Research Units in Southampton and Nottingham, clinical trial units in Manchester, Leicester, Glasgow, Belfast, Newcastle, Oxford, Sheffield and Norwich and commercial trial sites in Liverpool, Cardiff, Birmingham, Leeds and Reading, as well as five sites in Australia


As for the current COVID 19 trials it is not unreasonable to think that some if not all of these same sites will be part of the trials.

And spot another potential international link up!

There are numerous documents and links that highlight the promising progress of SG016 COPD trail to date and this one concludes similarly:

These Phase I and Phase II clinical trials have been highly successful and have shown that IFN-03b21a by inhalation is safe both in normal and asthmatic volunteers.

Further work undertaken by Synairgen internally and in collaboration with the Public Health England has shown IFN-03b2 has utility against established influenza (swine flu — H1N1, avian flu — H5N1 and seasonal flu) infection.

This is an old document, and these are just a few extracts, but for those who are unsure about Synairgen's credentials, and those who want a little more serious reading I can fully recommend a full read :-




I try to keep up with all links posted, so I apologise if this has gone before.


Exciting times.

Ferris
GLA, DYOR, NAI, & ATJ

[nobbygnome] 13/4/2020 13:39

Wow, now I am excited...which is unusual for a scientist!

First the caveats.

1. This study was done in moderate patients so not as severe as patients in the SG016 study, although the SG016 participants are not the most severe as patients who are ventilated are excluded.
2. The group who got IFN alone was very small (7 patients) and most also got arbidol (46 patients) so you cannot rule out a beneficial effect of the latter. However, clearly arbidol is not a very effective drug and is only approved in Russia and China.
3. The study was uncontrolled and by no means did each patient get treated the same
4. This study used interferon alpha not beta, although there is some suggestion that beta should be better
5. The dose was higher than in SG016 (5 million IUs twice daily rather than 6 million IUs once daily) although the delivery system seems not to be optimised so personally I don't think this is significant.

However, I think the positives greatly outweigh the negatives. There was a statistically significant effect on viral load and IL-6 levels in the interferon group. In particular the effect on IL-6 is of great interest to me because it shows that the drug is affecting inflammatory cells in a positive way. Il-6 is one of the inflammatory cytokines which when over produced can cause massive problems and so this is a very significant effect. Of course this also strongly suggests that the approach to neutralise IL-6 could well be effective.

So overall, although it is far from a perfect set of data with the caveats I list above, the statistical and biological significance of the data is highly encouraging. As I said earlier this is the most convincing scientific data I have seen and it increases my % chance of the ongoing trial working.

Of course all just IMHO and no investment advice intended!

[likya123] 13/4/2020 13:06

And this from lse board too..



What I find interesting is this statement.
"Specifically, none of 
the patients developed respiratory distress requiring prolonged oxygen supplementation ;
or intubation; consequently, none of the patients in this cohort required intensive care."


I believe Richard and those involved in the heavily oversubscribed £14 million know it works but these trials will just give the clinical data for strength and safety as confirmation. I can see the share price being well north of 5 quid shortly.

[d1nga] 13/4/2020 13:03

From the report..., most of us dopes will understand


Most importantly, IFN-α2b therapy appears to shorten duration of viral
shedding. Notably, reduction of markers of acute inflammation such as CRP and IL6
correlated with this shortened viral shedding, suggesting IFN-α2b acted along a
functional cause-effect chain where virally induced inflammation represents a
pathophysiological driver. Taken together, these findings elevate the biological
plausibility of IFN-α2b representing a therapy for COVID-19 disease.

[likya123] 13/4/2020 13:01

That's why we are very fortunate to have your expertise Nobby!

We look forwards to your full interpretation of the article.

[nobbygnome] 13/4/2020 12:55

So this is the sort of information which should move the share price. However, I doubt it will because I guess most people will struggle to understand it.

[nobbygnome] 13/4/2020 12:52

Great find likya!

On a quick read (I will read it thoroughly later) this paper gives superb, highly statistically significant scientific data to support that inhaled interferon treatment should work. This is probably the most compelling science I have seen so far and increases my estimate of the chance of SNG001 working.

Great stuff!

[likya123] 13/4/2020 12:37

From lse board...


Check out this article. Extremely technical, but seems to support use of interferon as a nebuliser for COVID19 anti-viral treatment.

[wetdream] 13/4/2020 12:19

Posted by ShareSting on LSE:

If you fancy reading about Synairgen’s US Patent.




Hope they’ve kept up their payments!

[ccr1958] 13/4/2020 11:30

I hearing some mush on NCYT board saying sauidis trialling our Drugs ?

[nobbygnome] 13/4/2020 11:20

>> Torreskid

You have to do the stand alone trial first so that you can determine if inhaled interferon beta is effective. Then you can proceed to combination studies to see if there is a symbiotic or additive effect. If you go straight to a combination study you will never know if both are really required.

Sticking just to SG016 is the correct approach. That way they will get a clean rapid answer as to whether the drug works. From that can stem multiple possibilities but just get he basic clean answer first!

[torreskid] 13/4/2020 11:13

Surprised that Inhaled IF-b is not used in Solidarity. Perhaps SNG just want to focus on their own trial.

I have previously said that I anticipate that SNG001 (may) is likely to have a greater effect in combination with oral anti-viral therapies. As in the effect is greater than the 'sum of all the parts'. Injected interferon may not have the same desired effect!

For the record, current Remdesivir trials (interim analysis) have not shown any positive results.

[toffeeman] 13/4/2020 10:57

SARS-CoV-2 sensitive to type I interferon pretreatment.

NB - this was in-vitro and so encouraging but not that helpful.

SNG trial is in-vivo

[likya123] 13/4/2020 10:55

Thanks Nobby but surely if the pilot is successful that is very good news?

[nobbygnome] 13/4/2020 10:52

>> likya

And I now have confirmation about the 400 patient number in the clinical trial protocol. Richard Marsden has told me that it is indeed a placeholder number for the expanded trial assuming the pilot is successful as I previously suggested.

So again nothing to get excited about.....there will not be an RNS about it tomorrow!

[nobbygnome] 13/4/2020 10:51

And I now have confirmation about the 400 patient number in the clinical trial protocol. Richard Marsden has told me that it is indeed a placeholder number for the expanded trial assuming the pilot is successful as I previously suggested.

So again nothing to get excited about.....

[nobbygnome] 13/4/2020 10:14

>> peachie

Yes you have to say the widespread interest in interferon beta is very encouraging. If people think injected drug is a possibility, then the chances of the drug delivered by inhalation direct to the site of action being successful is way higher IMHO!

And yes prophylactic use and stockpiling could make this drug absolutely massive.....

[peachie 74] 13/4/2020 10:12

Rather see 183 PTI !

[the patient investor] 13/4/2020 10:01

"83p on Tuesday at 13:47: DELIRIUM for the ordinary, REALITY for the visionary"


discASS

[peachie 74] 13/4/2020 09:42

If INF B was shown to be effective prophylactically , that would be massive.
Ridiculously massive. The world wide application would be huge